Researchers are exploring novel strategies to improve the efficacy and selectivity of RNR-targeting therapies. For instance, efforts are being made to develop combination therapies that use RNR inhibitors alongside other treatments to overcome resistance and enhance cancer cell killing. Additionally, advancements in drug delivery systems aim to target RNR inhibitors more precisely to cancer cells, minimizing collateral damage to normal tissues.
